Clinical Trials Logo

HIV Infections clinical trials

View clinical trials related to HIV Infections.

Filter by:

NCT ID: NCT03254550 Recruiting - Clinical trials for HIV Negative People Identified at Substantial Risk for HIV Infection

PrEP Demonstration Study in Swaziland

Start date: August 1, 2017
Phase: N/A
Study type: Observational

An 18 month observation cohort study with the overall aim to assess the operationalization of oral Pre-exposure prophylaxis (PrEP) in Swaziland as an additional HIV combination prevention method among population groups and individuals at high risk of HIV infection.

NCT ID: NCT03254277 Not yet recruiting - Clinical trials for Human Immunodeficiency Virus

3BNC117-LS First-in-Human Phase 1 Study

Start date: August 2017
Phase: Phase 1
Study type: Interventional

This study is a phase 1, open label, dose-escalation study of the mAb 3BNC117-LS administered intravenously in HIV (human immunodeficiency virus)-uninfected individuals and HIV-infected individuals. The objectives of the study are to evaluate the safety, tolerability and pharmacokinetics of a single infusion of 3BNC117-LS in HIV-uninfected and HIV-infected individuals.

NCT ID: NCT03253757 Not yet recruiting - HIV Infections Clinical Trials

PrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation

Start date: September 1, 2017
Phase: N/A
Study type: Observational

HIV pre-exposure prophylaxis (PrEP) is the use of anti-HIV medicines by HIV negative people in order to prevent them from becoming HIV positive if exposed to HIV. Currently, the combination drug containing tenofovir and emtricitabine is licensed in Europe for use as HIV PrEP. We know from previous studies worldwide that this combination drug is very good at reducing the risk of HIV infection and several countries have implemented PrEP programmes to provide PrEP to individuals at high risk of HIV. However, it is difficult to effectively plan for a national PrEP programme in England without knowing how many people will need PrEP, how many will want to take PrEP, and how long they will stay on PrEP. In order to find this out, the PrEP Impact Trial will make PrEP available to at least 10,000 people over three years. HIV negative men and women attending sexual health clinics in England will have their risk of HIV assessed by their care team and be offered PrEP if they meet the eligibility criteria. Through the trial we will be able to measure how many attendees at sexual health clinics meet eligibility criteria for PrEP, how many of these take up the offer of PrEP and how long they remain on PrEP for. There will not be any additional tests other than those recommended for the safe delivery of PrEP. These include tests for sexually transmitted infections (STIs) and HIV as well as urine and blood tests to monitor kidney function. Information about attendances and test results will be anonymously collected through the existing data reporting system that sexual health clinics currently use to report to Public Health England.

NCT ID: NCT03250910 Completed - Clinical trials for Human Immunodeficiency Virus

Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients

Start date: August 1, 2016
Phase: Phase 4
Study type: Interventional

Data are limited regarding the effectiveness and safety of generic velpatasvir plus sofosbuvir (VEL/SOF) with or without ribavirin (RBV) for the treatment of hepatitis C virus (HCV) in patients with human immunodeficiency virus (HIV) coinfection. We aim to compare the effectiveness and safety of VEL/SOF with and without RBV for 12 weeks in HIV/HCV-coinfected and HCV-monoinfected patients The antiviral responses and the adverse events (AEs) are compare between the two groups. The characteristics potentially related to sustained virologic response 12 weeks off therapy (SVR12) are analyzed.

NCT ID: NCT03239899 Recruiting - HIV Infections Clinical Trials

PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection

Start date: August 23, 2017
Phase: Phase 1
Study type: Interventional

Background: HIV affects millions of people. The disease may "hide" in the brain, even in people with well-controlled HIV without cancer. Then it may "wake up" and continue. The drug pembrolizumab uses the body s immune system to fight cells like cancer cells. It is approved to treat some cancers but not HIV. Researchers want to see if it is safe for HIV-positive people without cancer. This study is not for HIV treatment; only one dose of the drug will be used. Objective: To learn if the drug pembrolizumab, used to treat certain cancers, is safe for HIV-positive people. Eligibility: Adults ages 18 and older with HIV who are in another NIH protocol Design: Participants will be screened with: - Medical history - Physical and neurological exams - Blood tests - Lumbar puncture. The lower back will be numbed. A needle will remove fluid from between back bones. - FDG-PET/CT. A radioactive sugar will be injected in a thin plastic tube (catheter) inserted in an arm vein. Participants will rest for an hour, urinate, then lie in the scanner. A mask will hold the head still. Women who can become pregnant cannot take pembrolizumab. Men who take it must use 2 kinds of contraception. Participants will have up to 7 more visits, which repeat some screening tests. At 1 visit, participants will get one dose of pembrolizumab by catheter for 30 minutes. They will get allergy and pain medicines. At 2 visits, participants will have a brain MRI. They will get a contrast agent by catheter. They will lie in a metal cylinder that takes pictures for 1-2 hours. They will get earplugs for loud sounds.

NCT ID: NCT03239483 Not yet recruiting - HIV Infections Clinical Trials

Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults

Start date: September 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of dapivirine gel (0.05%) administered rectally to HIV-1 seronegative adults.

NCT ID: NCT03238755 Recruiting - HIV Infections Clinical Trials

Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins: A Cardiac MRI Study

Start date: July 31, 2017
Phase: N/A
Study type: Observational

In this study, investigators plan to test whether statins can preserve and/or improve diastolic function among asymptomatic persons with HIV who are on anti-retroviral therapy. Both myocardial fibrosis and myocardial steatosis are thought to contribute to diastolic dysfunction and eventually overt heart failure in HIV. HIV-positive participants will undergo cardiac MRI/MRS imaging studies for the evaluation of myocardial fibrosis and myocardial steatosis prior to initiation of statin or placebo therapy and then two years after initiation of statin or placebo therapy. Traditional markers of cardiovascular (CVD) risk, systemic immune activation/ inflammation, HIV-specific parameters (i.e. CD4 count), and markers of myocardial stretch/injury will be assessed in relation to cardiac MRI/MRS outcomes.

NCT ID: NCT03235518 Recruiting - Clinical trials for Human Immunodeficiency Virus

A Combination HIV Prevention Strategy for Young Women at Risk for HIV

IPrEP
Start date: June 28, 2017
Phase: N/A
Study type: Observational

The purpose of this study is to conduct formative research to inform the design and implementation of combination prevention interventions, including pre-exposure prophylaxis (PrEP) for female sex workers (FSW), as well as to inform recruitment and retention strategies for female sex workers and their male clients in Kenya.

NCT ID: NCT03235349 Not yet recruiting - Clinical trials for Hepatitis C Virus (HCV)

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment-Naïve and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection

Start date: September 8, 2017
Phase: Phase 3
Study type: Interventional

This is a Phase 3, single-arm, open-label, multicenter study to evaluate the efficacy and safety of ABT-493/ABT-530 in chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with compensated cirrhosis with or without Human Immunodeficiency Virus (HIV) co-infection who are HCV treatment-naïve or treatment-experienced with interferon (IFN) (alpha, beta or pegylated interferon [pegIFN]) with or without ribavirin (RBV) OR sofosbuvir with RBV with or without IFN.

NCT ID: NCT03234036 Recruiting - Clinical trials for Infection, Human Immunodeficiency Virus

A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir

Start date: August 2, 2017
Phase: Phase 1
Study type: Interventional

This study will be conducted in two Parts to confirm the acceptability/selection of a tablet formulation for future clinical development of GSK2838232. Part 1 of the study will assess single ritonavir (RTV)-boosted doses of a new tablet formulation given with food (containing approximately 30% fat) against the reference capsule formulation also given with food and then will assess the impact of fasted conditions on the tablet performance. In Part 2, non-boosted GSK2838232 will be given as once-daily tablet doses for 11 days in a separate group of subjects, assuming the tablet performance is considered acceptable from Part 1. Approximately 16 healthy subjects will be enrolled to provide at least 12 evaluable subjects through the three study periods in Part 1. 10 healthy subjects will be enrolled to provide at least 8 evaluable subjects through the single study period in Part 2. The maximum duration of study participation will be approximately 9 to 10 weeks for Part 1; and 8 to 9 weeks for Part 2.